These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 3274864)

  • 1. Anti-idiotypic autoantibodies after donor-specific blood transfusions.
    Toma H; Hayasaka Y; Yasuo M; Takahashi K; Teraoka S; Ota K
    Transplant Proc; 1987 Feb; 19(1 Pt 1):755-7. PubMed ID: 3274864
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the risk factors associated with donor specific blood transfusion.
    Vaidya S; Sommer BG; Pagel EA; Koegel M; Ferguson RM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2268. PubMed ID: 3274505
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiidiotypic antibody activity in patients receiving donor specific transfusions and cyclosporine A.
    Stewart KN; Power DA; Hills AN; Catto GR
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2262-3. PubMed ID: 3079078
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiidiotypic activity and sensitization after donor-specific transfusion (DST) given with and without cyclosporin A (CsA).
    Hillis AN; MacLeod AM; al-Muzairai IA; Innes A; Stewart KN; Power DA; Bone MJ; Sells RA; Catto GR
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1820-1. PubMed ID: 2652591
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of pretransplant antibodies on early renal allograft rejection.
    Alarif L; Rodriguez R; Blackburn S; Light JA
    Transplant Proc; 1987 Feb; 19(1 Pt 1):771-2. PubMed ID: 3274869
    [No Abstract]   [Full Text] [Related]  

  • 6. Graft survival with high levels of cytotoxic antibodies.
    Feduska NJ; Amend WJ; Vincenti F; Perkins HA; Opelz G; Terasaki PI; Iwaki Y; Duca R; Dodge D; Salvatierra O
    Transplant Proc; 1981 Mar; 13(1 Pt 1):73-80. PubMed ID: 7022910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of donor specific blood transfusions in prolongation of kidney graft survival.
    Matsumoto T; Sakagami K; Orita K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2264-7. PubMed ID: 2950636
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of dithiothreitol on a variety of evolutive patterns of anti-T and -B lymphocyte antibodies in renal transplant candidates.
    García de Masdevall MD; Arrieta A; Riñón M; Altés C; Arranz C
    Transplant Proc; 1992 Dec; 24(6):2505-7. PubMed ID: 1465847
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of donor-specific blood transfusion on in vitro alloreactive precursor cell frequencies.
    Duffy B; Tyler J; Anderson C; Hanto D; Flye W; Rodey G
    Transplant Proc; 1987 Feb; 19(1 Pt 1):753-4. PubMed ID: 2978930
    [No Abstract]   [Full Text] [Related]  

  • 10. Recipient sensitization against donor cells in pre- and/or posttransplantation sera is inversely correlated with graft survival.
    Sumitran S; Forsberg I; Lindholm A; Lundgren G; Möller E
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1566-7. PubMed ID: 3274384
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-idiotypic antibodies to HLA after donor-specific blood transfusion (DST).
    Pohanka E; Manfro RC; Oto C; Colombe BW; Melzer J; Feduska N; Salvatierra O; Garovoy MR
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1806-9. PubMed ID: 2652590
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduction of anti-HLA antibody using small-dose single-donor blood transfusion.
    Ettenger R; Cho S; Marik J; von Lilien T; Fine RN
    Transplant Proc; 1987 Feb; 19(1 Pt 1):740-2. PubMed ID: 3274859
    [No Abstract]   [Full Text] [Related]  

  • 13. False-positive crossmatch owing to autoantibodies induced by donor-specific transfusions without development of alloantibodies.
    López Blanco OA; Cavalli NH; Raimondi E; Haas EJ; Verruno L; Gotlieb D
    Transplant Proc; 1989 Feb; 21(1 Pt 1):768-70. PubMed ID: 2650264
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimization of donor specific blood transfusion in kidney transplantation.
    Cheigh JS; Suthanthiran M; Stubenbord WT; Fotino M; Riggio RR; Schechter N; Stenzel KH; Rubin AL
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2250-1. PubMed ID: 2978891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of the University of California at San Francisco experience with donor-specific blood transfusions.
    Salvatierra O; Iwaki Y; Vincenti F; Amend W; Terasaki P; Garovoy M; Duca R; Hopper S; Feduska N
    Transplant Proc; 1982 Jun; 14(2):363-6. PubMed ID: 7051480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-idiotypic activity in cytotoxic sera from highly sensitised patients (HSP) given cyclosporin A and blood transfusion from a specific donor (ST).
    al-Muzairai IA; MacLeod AM; Cochrane S; Jones MC; Propper D; Catto GR
    Transplant Proc; 1989 Feb; 21(1 Pt 1):748-9. PubMed ID: 2650254
    [No Abstract]   [Full Text] [Related]  

  • 17. Donor-specific flow cytometric cross-match after kidney transplantation.
    Puig N; Pallardó LM; Villalba JV; Sánchez J; Crespo J; Rodriguez R; Montoro JA
    Transplant Proc; 1995 Aug; 27(4):2369-70. PubMed ID: 7652842
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of anti-Fab and anti-IgG antibodies with high kidney transplant survival.
    Chia D; Horimi T; Terasaki PI; Hermes M
    Transplant Proc; 1982 Jun; 14(2):322-4. PubMed ID: 7051474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of donor-specific transfusions on long-term renal allograft function.
    Anderson CB; Brennan D; Keller C; Goss J; Shenoy S; Burton K; Sicard G; Flye MW
    Transplant Proc; 1995 Feb; 27(1):991-4. PubMed ID: 7879258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of pretransplant flow cytometric crossmatches with T and B lymphocytes in kidney transplantation.
    Berteli AJ; Daniel V; Pomer S; Opelz G
    Transplant Proc; 1990 Aug; 22(4):1895-6. PubMed ID: 2389477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.